HALOZYME THERAPEUTICS, INC. (HALO) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 1.66B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 292.42M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $1.66B | $292.42M | (m) |
| 2026-03-31 | (m) | $1.51B | $259.61M | (m) |
| 2025-12-31 | (m) | $1.40B | $228.77M | (m) |
| 2025-09-30 | (m) | $1.24B | $192.06M | (m) |
| 2025-06-30 | (m) | $1.18B | $186.24M | (m) |
| 2025-03-31 | (m) | $1.08B | $179.49M | (m) |
| 2024-12-31 | (m) | $1.02B | $159.42M | (m) |
| 2024-09-30 | (m) | $947.36M | $169.66M | (m) |
| 2024-06-30 | (m) | $873.30M | $175.06M | (m) |
| 2024-03-31 | (m) | $862.99M | $185.52M | (m) |
| 2023-12-31 | (m) | $829.25M | $192.36M | (m) |
| 2023-09-30 | (m) | $780.71M | $182.18M | (m) |
| 2023-06-30 | (m) | $773.65M | $174.68M | (m) |
| 2023-03-31 | (m) | $704.98M | $158.55M | (m) |
| 2022-12-31 | (m) | $660.12M | $139.30M | (m) |
| 2022-09-30 | (m) | $580.62M | $118.77M | (m) |
| 2022-06-30 | (m) | $487.48M | $90.04M | (m) |
| 2022-03-31 | (m) | $471.57M | $79.12M | (m) |
| 2021-12-31 | (m) | $443.31M | $81.41M | (m) |
| 2021-09-30 | (m) | $463.01M | $86.10M | (m) |
| 2021-06-30 | (m) | $412.50M | $73.08M | (m) |
| 2021-03-31 | (m) | $331.26M | $55.80M | (m) |
| 2020-12-31 | $12.62M | $267.59M | $43.37M | 4.72% |
| 2020-09-30 | (m) | $199.56M | $33.78M | (m) |
| 2020-06-30 | (m) | $180.47M | $50.55M | (m) |
| 2020-03-31 | (m) | $164.40M | $46.68M | (m) |
| 2019-12-31 | $20.50M | $195.99M | $45.55M | 10.46% |
| 2019-09-30 | (m) | $202.56M | (m) | (m) |
| 2019-06-30 | (m) | $181.88M | (m) | (m) |
| 2019-03-31 | (m) | $177.94M | (m) | (m) |
| 2018-12-31 | $18.10M | $151.86M | (m) | 11.92% |
| 2018-09-30 | (m) | $281.19M | (m) | (m) |
| 2018-06-30 | (m) | $319.37M | (m) | (m) |
| 2018-03-31 | (m) | $317.92M | (m) | (m) |
| 2017-12-31 | $19.24M | $316.61M | (m) | 6.08% |
| 2017-09-30 | (m) | $166.05M | (m) | (m) |
| 2017-06-30 | (m) | $134.17M | (m) | (m) |
| 2017-03-31 | (m) | $133.76M | (m) | (m) |
| 2016-12-31 | $16.84M | $146.69M | (m) | 11.48% |
| 2016-09-30 | (m) | $159.91M | (m) | (m) |
| 2016-06-30 | (m) | $148.84M | (m) | (m) |
| 2016-03-31 | (m) | $158.89M | (m) | (m) |
| 2015-12-31 | $16.84M | $135.06M | (m) | 12.47% |
| 2015-09-30 | (m) | $113.21M | (m) | (m) |
| 2015-06-30 | (m) | $107.03M | (m) | (m) |
| 2015-03-31 | (m) | $82.03M | (m) | (m) |
| 2014-12-31 | $15.09M | $75.33M | (m) | 20.03% |
| 2014-09-30 | (m) | $57.46M | (m) | (m) |
| 2014-06-30 | (m) | $58.86M | (m) | (m) |
| 2014-03-31 | (m) | $54.93M | (m) | (m) |
| 2013-12-31 | $18.19M | $54.80M | (m) | 33.20% |
| 2013-09-30 | (m) | $64.09M | (m) | (m) |
| 2013-06-30 | (m) | $53.42M | (m) | (m) |
| 2013-03-31 | (m) | $46.72M | (m) | (m) |
| 2012-12-31 | (m) | $42.33M | (m) | (m) |
| 2012-09-30 | (m) | $22.94M | (m) | (m) |
| 2012-06-30 | (m) | $40.55M | (m) | (m) |
| 2012-03-31 | (m) | $55.98M | (m) | (m) |
| 2011-12-31 | (m) | $56.09M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $13.62M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $13.67M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |